Liquidia (NASDAQ:LQDA) Given Buy Rating at Needham & Company LLC

Liquidia (NASDAQ:LQDA)‘s stock had its “buy” rating reissued by equities researchers at Needham & Company LLC in a note issued to investors on Thursday,Benzinga reports. They currently have a $19.00 price objective on the stock. Needham & Company LLC’s price target would suggest a potential upside of 93.09% from the company’s current price.

A number of other research analysts also recently weighed in on the stock. BTIG Research decreased their target price on shares of Liquidia from $29.00 to $25.00 and set a “buy” rating for the company in a research report on Monday, August 19th. Lifesci Capital initiated coverage on Liquidia in a report on Thursday, October 3rd. They set an “outperform” rating and a $30.00 target price on the stock. HC Wainwright reduced their price target on Liquidia from $32.00 to $29.00 and set a “buy” rating for the company in a research report on Tuesday, August 20th. Bank of America dropped their price objective on Liquidia from $24.00 to $23.00 and set a “buy” rating on the stock in a research note on Tuesday, August 20th. Finally, Scotiabank initiated coverage on shares of Liquidia in a report on Wednesday, October 16th. They set a “sector outperform” rating and a $30.00 target price on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Liquidia currently has a consensus rating of “Moderate Buy” and a consensus target price of $24.00.

Liquidia Stock Performance

NASDAQ LQDA opened at $9.84 on Thursday. Liquidia has a 52 week low of $6.10 and a 52 week high of $16.99. The stock’s 50 day moving average price is $10.52 and its two-hundred day moving average price is $11.49. The stock has a market capitalization of $755.61 million, a price-to-earnings ratio of -6.04 and a beta of 0.21.

Insider Transactions at Liquidia

In related news, General Counsel Russell Schundler sold 2,576 shares of the firm’s stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $11.11, for a total transaction of $28,619.36. Following the transaction, the general counsel now directly owns 486,048 shares of the company’s stock, valued at approximately $5,399,993.28. This trade represents a 0.53 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Rajeev Saggar sold 2,260 shares of the business’s stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $11.11, for a total transaction of $25,108.60. Following the completion of the sale, the insider now directly owns 207,383 shares of the company’s stock, valued at $2,304,025.13. This represents a 1.08 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 21,551 shares of company stock worth $236,021 over the last quarter. Company insiders own 30.10% of the company’s stock.

Institutional Trading of Liquidia

Several large investors have recently modified their holdings of LQDA. Quest Partners LLC acquired a new position in Liquidia in the second quarter valued at about $27,000. Hilltop National Bank acquired a new position in shares of Liquidia in the 2nd quarter valued at approximately $33,000. Clear Harbor Asset Management LLC bought a new stake in shares of Liquidia during the 3rd quarter worth approximately $100,000. Signaturefd LLC lifted its holdings in shares of Liquidia by 38,400.0% during the 3rd quarter. Signaturefd LLC now owns 10,010 shares of the company’s stock worth $100,000 after acquiring an additional 9,984 shares during the period. Finally, Ballentine Partners LLC acquired a new stake in shares of Liquidia during the 3rd quarter worth approximately $110,000. 64.54% of the stock is owned by institutional investors and hedge funds.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).